COSTS AND FORMULARY CONTEXT 6 November 2026 - review edition 6 EXISTING DISPENSING RECORDS Citalopram, 2024: 976,819 items; gross ingredient cost GBP 1,971,102.70; mean GIC/item GBP 2.0179. Citalopram, 2025: 939,305 items; gross ingredient cost GBP 1,919,681.03; mean GIC/item GBP 2.0437. Sertraline, 2024: 2,066,436 items; gross ingredient cost GBP 6,686,098.37; mean GIC/item GBP 3.2356. Sertraline, 2025: 2,135,974 items; gross ingredient cost GBP 6,910,007.40; mean GIC/item GBP 3.2351. The counts agree with the story. Gross ingredient cost was already retained in the reconciled monthly/board/chemical aggregates. Citalopram's two chemical codes are combined. No new patient dataset was used. The 2025 means round to GBP 3.24 for sertraline and GBP 2.04 for citalopram. This does not show an obvious sertraline advantage in the mean cost per item. It does not establish comparable treatment costs: strengths, quantities, preparations and prescription intervals can differ. GIC is not net NHS expenditure. These averages cannot identify a prescriber's motivation or the effect of a pricing policy. Do not infer savings or cost-driven substitution from them. GUIDANCE AS ONE PLAUSIBLE INFLUENCE NHS Highland's current formulary lists fluoxetine or sertraline as first-choice SSRIs and advises against initiating citalopram because of potential co-prescribing interactions. This supplies a concrete example of guidance that can influence medicine choice. It does not establish which version was in effect in each board throughout 2024-2025, whether a new policy occurred during the period, or whether that guidance caused the observed changes. The targeted historical guidance check found an August 2024 national publication and a February 2025 East Region liquid-formulation amendment. Movement before publication cannot rule out earlier influence or formalisation of existing practice. No dated early-circulation record was found. See prescribing_guidance_timing_check.txt; appropriately linked prescribing information would still be needed to examine causation. No claim about financial incentives is supported here. https://rightdecisions.scot.nhs.uk/tam-treatments-and-medicines-nhs-highland/formularies/highland-formulary/central-nervous-system/antidepressants/selective-serotonin-re-uptake-inhibitors-ssris-formulary/ Dated historical check: prescribing_guidance_timing_check.txt Data: https://www.opendata.nhs.scot/dataset/prescriptions-in-the-community